Factors associated with nonresponse to ovulation induction using XXXX among @entity1 with World Health Organization group II @entity3206 .

@entity1 @entity249 @entity4672 @entity4082 @entity3206 @entity53 @entity22300 @entity3427
CONTEXT: @entity4672 , a third generation aromatase inhibitor is gaining importance in ovulation induction. Some prefer to use it as a second line agent in @entity1 who fail to respond to @entity22300 . However, our knowledge about the predictors of response to @entity4672 is limited. AIMS: The study was aimed at identifying the factors associated with @entity4672 resistance among @entity1 with World Health Organization (WHO) group II @entity3206 . SUBJECTS AND METHODS: Study was conducted at the @entity249 clinic at a tertiary care hospital in Sri Lanka. A case-control study design was used and included 50 subjects with WHO group II @entity3206 (25 @entity4082 responsive and 25 @entity4082 resistant). After a treatment cycle of @entity4672 , the factors were compared between the subjects who responded and those who failed to respond to treatment. RESULTS: Ovulation was achieved in 76% (n = 19) of subjects who had responded to @entity4082 previously and in 24% (n = 6) with @entity4082 resistance. The factors associated with @entity4672 resistance included the presence of @entity3427 (odds ratio [OR]: 3.89; 95% confidence interval [CI]: 1.2-12.3) and @entity4082 resistance (OR: 10.03; 95% CI: 2.81-35.7). The early follicular phase mean (standard deviation) luteinizing hormone level was significantly higher among the nonresponders (9.75 [4.78] - 7.28 [2.3]; P = 0.02). Nonresponders showed significantly lower levels of @entity53 on the 5(th) and 9(th) days (28.50 [3.39] pg/mL vs. 7.49 [3.62] pg/mL; P = 0.0007 and 142.04 [76.22] pg/mL vs. 28.10 [12.8] pg/mL; P = 0.0001) of the menstrual cycle, respectively. CONCLUSIONS: The features associated with resistance to @entity4672 at a dose of 2.5 mg show some overlap with those associated with @entity4082 resistance. However, some features do not show similar association. The effectiveness of @entity4672 at a dose of 2.5 mg in induction of ovulation among @entity1 with @entity4082 resistance is low and it does not seem to be a suitable treatment at a dose of 2.5 mg for this indication.
